Chemomab Therapeutics Ltd DRC (CMMB) Stock Analysis

Chemomab Therapeutics Ltd DRC (CMMB) is a publicly traded company in the HEALTHCARE sector. It trades at $1.74, carries a market capitalization of $14.40M. This page summarizes the public market data, fundamentals, and frequently asked questions for CMMB, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.74
• Market Cap: $14.40M
• EPS: $-1.12
• 52-Week High: $5.52
• 52-Week Low: $1.35

Market Sentiment

Chemomab Therapeutics Ltd DRC currently has a Bullish sentiment score of 0.23.

About Chemomab Therapeutics Ltd DRC

Chemomab Therapeutics Ltd. is a clinical-stage biopharmaceutical firm headquartered in Tel Aviv, Israel, specializing in the development of innovative biological therapies for inflammatory and fibrotic diseases. The company’s lead candidate, CM-101, is a monoclonal antibody that targets critical pathways associated with fibrosis, demonstrating promise across multiple therapeutic indications. Chemomab is dedicated to harnessing its proprietary technology platform to deliver transformative trea...

GNG Research Analysis

GNG Research scores Chemomab Therapeutics Ltd DRC (CMMB) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CMMB.

Frequently Asked Questions

Does CMMB pay dividends?

Chemomab Therapeutics Ltd DRC (CMMB) does not currently pay a regular dividend.

What is CMMB's market cap?

Chemomab Therapeutics Ltd DRC (CMMB) has a market capitalization of $14.40M with a current stock price of $1.74.